136 related articles for article (PubMed ID: 16319976)
1. Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M; Cole DE; Gainford MC
Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
[TBL] [Abstract][Full Text] [Related]
2. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
3. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
[TBL] [Abstract][Full Text] [Related]
4. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
5. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
Kosteva J; Langer C
Curr Opin Oncol; 2008 Mar; 20(2):155-61. PubMed ID: 18300765
[TBL] [Abstract][Full Text] [Related]
6. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
7. Bone markers in the management of patients with skeletal metastases.
Demers LM
Cancer; 2003 Feb; 97(3 Suppl):874-9. PubMed ID: 12548589
[TBL] [Abstract][Full Text] [Related]
8. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
10. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
11. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?
Lipton A; Costa L; Coleman RE
Breast Dis; 2011; 33(2):59-69. PubMed ID: 22142664
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S138-47. PubMed ID: 14600604
[TBL] [Abstract][Full Text] [Related]
15. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
16. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
19. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
Mountzios G; Ramfidis V; Terpos E; Syrigos KN
Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
